2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
Harms M, Cho K, Anticevic A, Bolo N, Bouix S, Campbell D, Cannon T, Cecchi G, Goncalves M, Haidar A, Hughes D, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman J, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack R, Rathi Y, Romo P, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Kahn R, Kane J, McGorry P, Nelson B, Woods S, Shenton M, Wood S, Bearden C, Pasternak O. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 52. PMID: 40175382, PMCID: PMC11965426, DOI: 10.1038/s41537-025-00581-6.Peer-Reviewed Original ResearchClinical high riskSchizophrenia ProgramClinical high-risk cohortClinical high-risk stateResting-state fMRIFMRI scanningStudy of individualsNeuroimaging resultsBrain regionsNeuroimaging dataNeuroimaging protocolsStructural scansParticipation varianceDiffusion scansFMRIPercentage of participantsNeuroimagingVariance component analysisMulti-siteParticipantsPsychosisVarianceTime pointsDiffusion-weighted imagingHigh risk
2024
Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study
Byrne J, Healy C, Föcking M, Susai S, Mongan D, Wynne K, Kodosaki E, Heurich M, de Haan L, Hickie I, Smesny S, Thompson A, Markulev C, Young A, Schäfer M, Riecher-Rössler A, Mossaheb N, Berger G, Schlögelhofer M, Nordentoft M, Chen E, Verma S, Nieman D, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, McGorry P, Amminger P, Cagney G, Nelson B, Jeffries C, Perkins D, Cotter D. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin 2024, 50: 579-588. PMID: 38243809, PMCID: PMC11059811, DOI: 10.1093/schbul/sbad184.Peer-Reviewed Original ResearchClinical high riskTransition to psychosisAssociated with transition to psychosisClinical high-risk cohortNorth American Prodrome Longitudinal Study 2Predicting transition to psychosisDevelopment of psychosisLongitudinal Study 2Group levelPlasma proteomics dataCHR participantsPsychosis riskPrediction of transitionPsychosisStudy 2High riskLongitudinal associationsStudy follow-up periodRandomized Controlled TrialsLogistic regression modelsMultiple comparisonsPrimary outcomeProteomic biomarkersControlled TrialsGlycoprotein 1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply